In bid to extend cash runway, Cara to lay off workers, discontinue PhIII program in chronic kidney disease

Cara Therapeutics is cutting its workforce by nearly 50% and ending a Phase III program investigating an oral version of its opioid peptide in patients with chronic kidney disease.

The Stamford, CT-based biotech has been investigating oral difelikefalin against different diseases that cause pruritus — the medical term for itching — but it has faced multiple hurdles in recent months.

By conducting layoffs that include the exit of its head of R&D Frédérique Menzaghi and shuttering its chronic kidney disease program, the company now expects to extend its cash runway into 2026. It had 106 employees as of March 2023.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。